
Michael M Ward

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8070709/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases, 2019, 78, 1296-1304.	0.9	664
2	Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nature Genetics, 2010, 42, 123-127.	21.4	573
3	Patient Participation in Medical Consultations. Medical Care, 2005, 43, 960-969.	2.4	476
4	Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis and Rheumatism, 1999, 42, 338-346.	6.7	462
5	Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis and Rheumatism, 2005, 52, 2625-2636.	6.7	428
6	2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 1599-1613.	5.6	401
7	The Impact of Tumor Necrosis Factor α Inhibitors on Radiographic Progression in Ankylosing Spondylitis. Arthritis and Rheumatism, 2013, 65, 2645-2654.	6.7	391
8	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2016, 68, 282-298.	5.6	383
9	Risk of Endâ€Stage Renal Disease in Patients With Lupus Nephritis, 1971–2015: A Systematic Review and Bayesian Metaâ€Analysis. Arthritis and Rheumatology, 2016, 68, 1432-1441.	5.6	352
10	2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care and Research, 2019, 71, 1285-1299.	3.4	274
11	Health-related quality of life in ankylosing spondylitis: A survey of 175 patients. Arthritis and Rheumatism, 1999, 12, 247-255.	6.7	260
12	Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: Estimates obtained using hospitalization data. Arthritis and Rheumatism, 2007, 56, 2092-2094.	6.7	248
13	Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis and Rheumatism, 2006, 54, 2784-2792.	6.7	241
14	Long-term survival in systemic lupus erythematosus patient characteristics associated with poorer outcomes. Arthritis and Rheumatism, 1995, 38, 274-283.	6.7	228
15	Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Annals of the Rheumatic Diseases, 2007, 66, 633-638.	0.9	225
16	Mortality and causes of death in systemic lupus erythematosus. Current Opinion in Rheumatology, 2001, 13, 345-351.	4.3	211
17	Patient education interventions in osteoarthritis and rheumatoid arthritis: A meta-analytic comparison with nonsteroidal antiinflammatory drug treatment. Arthritis and Rheumatism, 1996, 9, 292-301.	6.7	201
18	Pneumocystis carinii pneumonia in patients with connective tissue diseases: The role of hospital experience in diagnosis and mortality. Arthritis and Rheumatism, 1999, 42, 780-789.	6.7	192

#	Article	IF	CITATIONS
19	Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Annals of the Rheumatic Diseases, 2017, 76, 2009-2016.	0.9	155
20	Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Populationâ€Based Study, 1996–2011. Arthritis Care and Research, 2015, 67, 1078-1085.	3.4	138
21	Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis and Rheumatism, 2002, 46, 223-231.	6.7	130
22	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2022, 81, 768-779.	0.9	128
23	Epidemiology of axial spondyloarthritis: an update. Current Opinion in Rheumatology, 2018, 30, 137-143.	4.3	126
24	Clinical Prognostic Factors in Lupus Nephritis. Archives of Internal Medicine, 1992, 152, 2082.	3.8	125
25	Time perspective and socioeconomic status: A link to socioeconomic disparities in health?. Social Science and Medicine, 2009, 68, 2145-2151.	3.8	125
26	Mortality Risks Associated With Specific Clinical Manifestations of Systemic Lupus Erythematosus. Archives of Internal Medicine, 1996, 156, 1337.	3.8	122
27	Socioeconomic Status and the Incidence of ESRD. American Journal of Kidney Diseases, 2008, 51, 563-572.	1.9	118
28	Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis and Rheumatism, 2009, 61, 859-866.	6.7	113
29	Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983-2007. Annals of the Rheumatic Diseases, 2010, 69, 868-871.	0.9	111
30	Risk factors for functional limitations in patients with longâ€standing ankylosing spondylitis. Arthritis and Rheumatism, 2005, 53, 710-717.	6.7	110
31	Changes in the Incidence of Endstage Renal Disease Due to Lupus Nephritis in the United States, 1996–2004. Journal of Rheumatology, 2009, 36, 63-67.	2.0	109
32	Participatory patient-physician communication and morbidity in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 49, 810-818.	6.7	98
33	Decreases in rates of hospitalizations for manifestations of severe rheumatoid arthritis, 1983-2001. Arthritis and Rheumatism, 2004, 50, 1122-1131.	6.7	96
34	QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS. Rheumatic Disease Clinics of North America, 1998, 24, 815-827.	1.9	93
35	Predictors of the progression of functional disability in patients with ankylosing spondylitis. Journal of Rheumatology, 2002, 29, 1420-5.	2.0	88
36	Ankylosing Spondylitis: Patterns of Radiographic Involvement—A Re-examination of Accepted Principles in a Cohort of 769 Patients. Radiology, 2011, 258, 192-198.	7.3	87

#	Article	IF	CITATIONS
37	Changes in the Incidence of End-stage Renal Disease Due to Lupus Nephritis, 1982-1995. Archives of Internal Medicine, 2000, 160, 3136.	3.8	81
38	Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Annals of the Rheumatic Diseases, 2015, 74, 1691-1696.	0.9	79
39	Exercise and Changes in Health Status in Patients With Ankylosing Spondylitis. Archives of Internal Medicine, 2000, 160, 2969.	3.8	78
40	Short-term prediction of mortality in patients with systemic lupus erythematosus: Classification of outcomes using random forests. Arthritis and Rheumatism, 2006, 55, 74-80.	6.7	78
41	Occupational physical activities and longâ€ŧerm functional and radiographic outcomes in patients with ankylosing spondylitis. Arthritis and Rheumatism, 2008, 59, 822-832.	6.7	72
42	Clinically Important Changes in Short Form 36 Health Survey Scales for Use in Rheumatoid Arthritis Clinical Trials: The Impact of Low Responsiveness. Arthritis Care and Research, 2014, 66, 1783-1789.	3.4	70
43	Recent improvements in survival in patients with rheumatoid arthritis: Better outcomes or different study designs?. Arthritis and Rheumatism, 2001, 44, 1467-1469.	6.7	67
44	Impact of ankylosing spondylitis on work and family life: Comparisons with the US population. Arthritis and Rheumatism, 2008, 59, 497-503.	6.7	67
45	Marital status and the progression of functional disability in patients with rheumatoid arthritis. Arthritis and Rheumatism, 1993, 36, 581-588.	6.7	62
46	Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Populationâ€Based Cohort Study. Arthritis and Rheumatology, 2016, 68, 1415-1421.	5.6	58
47	Education level and mortality in systemic lupus erythematosus (SLE): Evidence of underascertainment of deaths due to SLE in ethnic minorities with low education levels. Arthritis and Rheumatism, 2004, 51, 616-624.	6.7	57
48	Cardiovascular and cerebrovascular morbidity and mortality among women with end-stage renal disease attributable to lupus nephritis. American Journal of Kidney Diseases, 2000, 36, 516-525.	1.9	55
49	Thirtyâ€Day Hospital Readmissions in Systemic Lupus Erythematosus: Predictors and Hospital―and Stateâ€Level Variation. Arthritis and Rheumatology, 2014, 66, 2828-2836.	5.6	54
50	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care and Research, 2016, 68, 151-166.	3.4	53
51	Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open, 2019, 5, e000924.	3.8	52
52	HLA class I and II alleles in susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases, 2019, 78, 66-73.	0.9	52
53	Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis. Arthritis Research and Therapy, 2009, 11, R182.	3.5	51
54	Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2021, 80, 1168-1174.	0.9	49

#	Article	IF	CITATIONS
55	Avoidable hospitalizations in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2008, 59, 162-168.	6.7	47
56	MICA, a gene contributing strong susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases, 2014, 73, 1552-1557.	0.9	47
57	Advances in the treatment of inflammatory arthritis. Best Practice and Research in Clinical Rheumatology, 2012, 26, 251-261.	3.3	46
58	Economic Considerations of the Treatment of Ankylosing Spondylitis. American Journal of the Medical Sciences, 2012, 343, 371-374.	1.1	45
59	Ethnic and socioeconomic disparities in health among patients with rheumatic disease. Current Opinion in Rheumatology, 2005, 17, 147-152.	4.3	44
60	Quality of Care for Incident Lupus Nephritis Among Medicaid Beneficiaries in the United States. Arthritis Care and Research, 2014, 66, 617-624.	3.4	44
61	Brief Report: Trends in Hospitalizations Due to Acute Coronary Syndromes and Stroke in Patients With Systemic Lupus Erythematosus, 1996 to 2012. Arthritis and Rheumatology, 2016, 68, 2680-2685.	5.6	43
62	Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci. , 2020, 61, 3.		43
63	Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 48, 2519-2523.	6.7	42
64	Syndesmophyte growth in ankylosing spondylitis. Current Opinion in Rheumatology, 2015, 27, 326-332.	4.3	42
65	Hospital experience and mortality in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1999, 42, 891-898.	6.7	41
66	Outcomes of hospitalizations for myocardial infarctions and cerebrovascular accidents in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2004, 50, 3170-3176.	6.7	41
67	Sense of Control and Self-Reported Health in a Population-Based Sample of Older Americans: Assessment of Potential Confounding by Affect, Personality, and Social Support. International Journal of Behavioral Medicine, 2013, 20, 140-147.	1.7	39
68	Identification of clinically important changes in health status using receiver operating characteristic curves. Journal of Clinical Epidemiology, 2000, 53, 279-284.	5.0	37
69	Association between physician volume and in-hospital mortality in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 1646-1654.	6.7	37
70	Access to Care and the Incidence of End-Stage Renal Disease Due to Diabetes. Diabetes Care, 2009, 32, 1032-1036.	8.6	37
71	Access to Care and the Incidence of Endstage Renal Disease Due to Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 1158-1163.	2.0	37
72	Public knowledge of automatic external defibrillators in a large U.S. urban community. Resuscitation, 2015, 92, 101-106.	3.0	37

5

#	Article	IF	CITATIONS
73	Psychological Correlates of Self-reported Disease Activity in Ankylosing Spondylitis. Journal of Rheumatology, 2010, 37, 829-834.	2.0	36
74	Computer Aided Evaluation of Ankylosing Spondylitis Using High-Resolution CT. IEEE Transactions on Medical Imaging, 2008, 27, 1252-1267.	8.9	33
75	Quantitative measurement of syndesmophyte volume and height in ankylosing spondylitis using CT. Annals of the Rheumatic Diseases, 2014, 73, 544-550.	0.9	31
76	Quantitative syndesmophyte measurement in ankylosing spondylitis using CT: longitudinal validity and sensitivity to change over 2â€years. Annals of the Rheumatic Diseases, 2015, 74, 437-443.	0.9	31
77	Brief Report: Rheumatoid Arthritis Response Criteria and Patientâ€Reported Improvement in Arthritis Activity: Is an American College of Rheumatology Twenty Percent Response Meaningful to Patients?. Arthritis and Rheumatology, 2014, 66, 2339-2343.	5.6	30
78	Time perspective and medication adherence among individuals with hypertension or diabetes mellitus. Patient Education and Counseling, 2014, 95, 104-110.	2.2	30
79	Concordance of sibling's recall of measures of childhood socioeconomic position. BMC Medical Research Methodology, 2011, 11, 147.	3.1	29
80	Medical insurance, socioeconomic status, and age of onset of endstage renal disease in patients with lupus nephritis. Journal of Rheumatology, 2007, 34, 2024-7.	2.0	29
81	Laboratory testing for systemic rheumatic diseases. Postgraduate Medicine, 1998, 103, 93-100.	2.0	28
82	Medication toxicity among patients with ankylosing spondylitis. Arthritis and Rheumatism, 2002, 47, 234-241.	6.7	28
83	Outcome measurement: health status and quality of life. Current Opinion in Rheumatology, 2004, 16, 96-101.	4.3	28
84	Chylous ascites in cirrhosis: A case report and review of the literature. Journal of Gastroenterology and Hepatology (Australia), 1989, 4, 95-99.	2.8	27
85	Laboratory Abnormalities at the Onset of Treatment of End-Stage Renal Disease. Archives of Internal Medicine, 2007, 167, 1083.	3.8	26
86	Time Perspective and Smoking, Obesity, and Exercise in a Community Sample. American Journal of Health Behavior, 2013, 37, 171-180.	1.4	26
87	Domain-specific transition questions demonstrated higher validity than global transition questions as anchors for clinically important improvement. Journal of Clinical Epidemiology, 2015, 68, 655-661.	5.0	26
88	Reducing attrition bias with an instrumental variable in a regression model: Results from a panel of rheumatoid arthritis patients. Statistics in Medicine, 1993, 12, 1005-1018.	1.6	25
89	Association of measured physical performance and demographic and health characteristics with self-reported physical function: implications for the interpretation of self-reported limitations. Health and Quality of Life Outcomes, 2010, 8, 84.	2.4	25
90	Sense of control and sociodemographic differences in self-reported health in older adults. Quality of Life Research, 2012, 21, 1509-1518.	3.1	25

#	Article	IF	CITATIONS
91	Direct and Indirect Determinants of the Patient Global Assessment in Rheumatoid Arthritis: Differences by Level of Disease Activity. Arthritis Care and Research, 2017, 69, 323-329.	3.4	25
92	Trends in hospitalizations forPneumocystis jirovecipneumonia among patients with rheumatoid arthritis in the US: 1996-2007. Arthritis and Rheumatism, 2010, 62, 3826-3827.	6.7	24
93	Relative sensitivity to change of the erythrocyte sedimentation rate and serum C-reactive protein concentration in rheumatoid arthritis. Journal of Rheumatology, 2004, 31, 884-95.	2.0	24
94	Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: Differences in early and late disease. Arthritis Care and Research, 2013, 65, 257-265.	3.4	23
95	A qualitative approach exploring the acceptability of yoga for minorities living with arthritis: â€`Where are the people who look like me?'. Complementary Therapies in Medicine, 2017, 31, 82-89.	2.7	23
96	Dependence of the minimal clinically important improvement on the baseline value is a consequence of floor and ceiling effects and not different expectations by patients. Journal of Clinical Epidemiology, 2014, 67, 689-696.	5.0	22
97	Zygapophyseal Joint Fusion in Ankylosing Spondylitis Assessed by Computed Tomography: Associations with Syndesmophytes and Spinal Motion. Journal of Rheumatology, 2017, 44, 1004-1010.	2.0	22
98	Time Perspective and Exercise, Obesity, and Smoking: Moderation of Associations by Age. American Journal of Health Promotion, 2014, 29, 9-16.	1.7	21
99	Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis. Arthritis Care and Research, 2020, 72, 1645-1652.	3.4	21
100	Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort. Journal of Rheumatology, 2018, 45, 188-194.	2.0	20
101	Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid Arthritis. Journal of Rheumatology, 2019, 46, 27-30.	2.0	20
102	Treatments Used by Patients with Ankylosing Spondylitis Comparison with the Treatment Preferences of Rheumatologists. Journal of Clinical Rheumatology, 1999, 5, 1-8.	0.9	19
103	Prospects for disease modification in ankylosing spondylitis: Do nonsteroidal antiinflammatory drugs do more than treat symptoms?. Arthritis and Rheumatism, 2005, 52, 1634-1636.	6.7	19
104	Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis. Journal of Rheumatology, 2018, 45, 481-490.	2.0	19
105	Hospital experience and mortality in patients with systemic lupus erythematosus: which patients benefit most from treatment at highly experienced hospitals?. Journal of Rheumatology, 2002, 29, 1198-206.	2.0	19
106	A pilot study of yoga as self-care for arthritis in minority communities. Health and Quality of Life Outcomes, 2013, 11, 55.	2.4	18
107	Regional Variation in Rates of Total Knee Arthroplasty Among Medicare Beneficiaries. JAMA Network Open, 2020, 3, e203717.	5.9	18
108	Spatial distribution of syndesmophytes along the vertebral rim in ankylosing spondylitis: preferential involvement of the posterolateral rim. Annals of the Rheumatic Diseases, 2016, 75, 1951-1957.	0.9	17

#	Article	IF	CITATIONS
109	Computed tomography in axial spondyloarthritis. Current Opinion in Rheumatology, 2018, 30, 334-339.	4.3	17
110	Complications of Total Hip Arthroplasty in Patients With Ankylosing Spondylitis. Arthritis Care and Research, 2019, 71, 1101-1108.	3.4	17
111	Medications received by patients with juvenile dermatomyositis. Seminars in Arthritis and Rheumatism, 2018, 48, 513-522.	3.4	16
112	Increased Rates of Both Knee and Hip Arthroplasties in Older Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2019, 46, 31-37.	2.0	14
113	Evaluative laboratory testing. Arthritis and Rheumatism, 1995, 38, 1555-1563.	6.7	13
114	The contribution of disease activity on functional limitations over time through psychological mediators: a 12-month longitudinal study in patients with ankylosing spondylitis. Rheumatology, 2011, 50, 2087-2092.	1.9	13
115	Nonsteroidal Antiinflammatory Drugs as Potential Diseaseâ€Modifying Medications in Axial Spondyloarthritis. Arthritis and Rheumatology, 2020, 72, 518-528.	5.6	13
116	Belimumab as Add-on Therapy in Lupus Nephritis. New England Journal of Medicine, 2020, 383, 1184-1185.	27.0	13
117	Risks of solid cancers in elderly persons with osteoarthritis or ankylosing spondylitis. Rheumatology, 2020, 59, 3817-3825.	1.9	13
118	Improved precision of syndesmophyte measurement for the evaluation of ankylosing spondylitis using CT: a phantom and patient study. Physics in Medicine and Biology, 2012, 57, 4683-4704.	3.0	12
119	Interhospital variation in mortality among patients with systemic lupus erythematosus and sepsis in the USA. Rheumatology, 2019, 58, 1794-1801.	1.9	12
120	Rheumatology care, patient expectations, and the limits of time. Arthritis and Rheumatism, 2004, 51, 307-308.	6.7	11
121	Parental educational attainment and sense of control in mid- and late-adulthood Developmental Psychology, 2013, 49, 1407-1412.	1.6	11
122	Patient-centered care and health outcomes. Current Opinion in Rheumatology, 2004, 16, 89-90.	4.3	10
123	Thoracic Syndesmophytes Commonly Occur in the Absence of Lumbar Syndesmophytes in Ankylosing Spondylitis: A Computed Tomography Study. Journal of Rheumatology, 2017, 44, 1828-1832.	2.0	10
124	Racial/Ethnic Differences in Dialysis Discontinuation and Survival after Hospitalization for Serious Conditions among Patients on Maintenance Dialysis. Journal of the American Society of Nephrology: JASN, 2020, 31, 149-160.	6.1	10
125	Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis. JAMA Network Open, 2022, 5, e222312.	5.9	10
126	Functional Limitations Due to Axial and Peripheral Joint Impairments in Patients With Ankylosing Spondylitis: Are Focused Measures More Informative?. Arthritis Care and Research, 2013, 65, 607-614.	3.4	9

#	Article	IF	CITATIONS
127	Recent Clinical Trials in Lupus Nephritis. Rheumatic Disease Clinics of North America, 2014, 40, 519-535.	1.9	9
128	Quantitation of Circumferential Syndesmophyte Height along the Vertebral Rim in Ankylosing Spondylitis Using Computed Tomography. Journal of Rheumatology, 2015, 42, 472-478.	2.0	9
129	Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis. Rheumatology, 2021, 60, 2134-2145.	1.9	9
130	Interpreting studies of cardiovascular mortality in rheumatoid arthritis: The importance of timing. Arthritis and Rheumatism, 2008, 59, 1687-1689.	6.7	8
131	Medicare reimbursement and the use of biologic agents: Incentives, access, the public good, and optimal care. Arthritis Care and Research, 2010, 62, 293-295.	3.4	8
132	Personalized Therapeutics: A Potential Threat to Health Equity. Journal of General Internal Medicine, 2012, 27, 868-870.	2.6	8
133	Standards of Comparison and Discordance in Rheumatoid Arthritis Global Assessments Between Patients and Clinicians. Arthritis Care and Research, 2017, 69, 1260-1265.	3.4	8
134	Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort. Rheumatology International, 2020, 40, 1053-1061.	3.0	8
135	Osteoarthritis care and risk of total knee arthroplasty among medicare beneficiaries. Arthritis and Rheumatology, 2021, 73, 2261-2270.	5.6	8
136	Response criteria and criteria for clinically important improvement: Separate and equal?. Arthritis and Rheumatism, 2001, 44, 1728-1729.	6.7	7
137	Dynamics of syndesmophyte growth in AS as measured by quantitative CT: heterogeneity within and among vertebral disc spaces. Rheumatology, 2015, 54, 972-980.	1.9	7
138	Feasibility and assessment of outcome measures for yoga as self-care for minorities with arthritis: a pilot study. Pilot and Feasibility Studies, 2018, 4, 53.	1.2	7
139	Risk of total knee arthroplasty in young and middle-aged adults with ankylosing spondylitis. Clinical Rheumatology, 2018, 37, 3431-3433.	2.2	7
140	Validation of English and Spanish-language versions of a screening questionnaire for rheumatoid arthritis in an underserved community. Journal of Rheumatology, 2008, 35, 1545-9.	2.0	7
141	Interpreting measurements of physical function in clinical trials. Annals of the Rheumatic Diseases, 2007, 66, iii32-iii34.	0.9	6
142	Screening for depression in arthritis populations: an assessment of differential item functioning in three self-reported questionnaires. Quality of Life Research, 2017, 26, 2507-2517.	3.1	6
143	Aortic-vertebral interaction in ankylosing spondylitis: syndesmophyte development at the juxta-aortic vertebral rim. Annals of the Rheumatic Diseases, 2019, 78, 922-928.	0.9	6
144	Severity of illness in patients with systemic lupus erythematosus hospitalized at academic medical centers. Journal of Rheumatology, 2005, 32, 27-33.	2.0	6

#	Article	IF	CITATIONS
145	Vertebral Bone Mineral Density, Vertebral Strength, and Syndesmophyte Growth in Ankylosing Spondylitis: The Importance of Bridging. Arthritis and Rheumatology, 2022, 74, 1352-1362.	5.6	6
146	Clinical epidemiology: diagnostic and prognostic tests. Current Opinion in Rheumatology, 2003, 15, 104-109.	4.3	5
147	RA treatment study group: Improvement in RA management. Joint Bone Spine, 2009, 76, 435-437.	1.6	5
148	Measures of Arthritis Activity Associated With Patientâ€Reported Improvement in Rheumatoid Arthritis When Assessed Prospectively Versus Retrospectively. Arthritis Care and Research, 2015, 67, 776-781.	3.4	5
149	Better Quantification of Syndesmophyte Growth in Axial Spondyloarthritis. Current Rheumatology Reports, 2018, 20, 46.	4.7	5
150	Social and Economic Consequences. , 2006, , 214-224.		5
151	Testing the construct validity of a health transition question using vignette-guided patient ratings of health. Health and Quality of Life Outcomes, 2018, 16, 2.	2.4	4
152	Regional Variation in Surgical Procedure Rates. JAMA Surgery, 2021, , .	4.3	4
153	Inter-hospital transfers of patients with systemic lupus erythematosus: characteristics, predictors, and outcomes. Journal of Rheumatology, 2006, 33, 1578-85.	2.0	4
154	Primer: measuring the effects of treatment in clinical trials. Nature Clinical Practice Rheumatology, 2007, 3, 291-297.	3.2	3
155	The JUPITER study: statins for the primary prevention of cardiovascular events in patients with inflammatory rheumatic diseases?. F1000 Medicine Reports, 2009, 1, 35.	2.9	3
156	Response to: â€~Correspondence on â€~EULAR recommendations for the management of antiphospholipid syndrome in adults' by Zhou <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e249-e249.	0.9	3
157	The changing profile of ankylosing spondylitis in the biologic era. Clinical Rheumatology, 2020, 39, 2641-2651.	2.2	3
158	The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort. Journal of Rheumatology, 2021, , jrheum.210332.	2.0	3
159	Update on the American College of Rheumatology/Spondyloarthritis Research and Treatment Network/Spondylitis Association of America axial spondyloarhtritis treatment guidelines project. Clinical Rheumatology, 2014, 33, 739-740.	2.2	2
160	Applicability of patient utilities as measures of overall quality of life in rheumatoid arthritis clinical trials. Rheumatology, 2017, 56, 239-246.	1.9	2
161	Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis. Rheumatology, 2020, 59, 3917-3926.	1.9	2
162	Trends in Permanent Work Disability Associated With Rheumatoid Arthritis in the United States, 1999–2015. Arthritis Care and Research, 2022, 74, 1321-1324.	3.4	2

#	Article	IF	CITATIONS
163	Pneumocystis carinii pneumonia in patients with connective tissue diseases: The role of hospital experience in diagnosis and mortality. Arthritis and Rheumatism, 1999, 42, 780.	6.7	2
164	Sulfasalazine for the treatment of ankylosing spondylitis: Relic or niche medication?. Arthritis and Rheumatism, 2011, 63, 1472-1474.	6.7	1
165	Origins of Discordant Responses among 3 Rheumatoid Arthritis Improvement Criteria. Journal of Rheumatology, 2018, 45, 745-752.	2.0	1
166	Validity of health transition questions is supported by larger clinical improvements in purposive samples enriched for improvers. Journal of Clinical Epidemiology, 2019, 116, 138-139.	5.0	1
167	Socioeconomic and Disability Aspects. , 2019, , 759-769.		1
168	Translating Treatment Effects Between Rheumatoid Arthritis Activity Measures and American College of Rheumatology Responses in Direct Comparison Trials. Arthritis Care and Research, 2019, 71, 1482-1487.	3.4	1
169	Chronic oral anticoagluation and risk of prostate cancer: Evidence of detection bias. International Journal of Cancer, 2020, 146, 3022-3025.	5.1	1
170	Accuracy of diagnoses of inflammatory arthritis in administrative hospitalization databases. Pharmacoepidemiology and Drug Safety, 2021, 30, 257-265.	1.9	1
171	Response to: â€~Correspondence on â€~EULAR recommendations for the management of antiphospholipid syndrome in adults'' by Gao and Qin. Annals of the Rheumatic Diseases, 2023, 82, e107-e107.	0.9	1
172	Estimates of minimal clinically important improvments vary with the responsiveness of the sample. Journal of Clinical Epidemiology, 2022, 142, 110-118.	5.0	1
173	Sacroiliac Bone Marrow Edema: Innocent Until Proven Guilty?. Arthritis and Rheumatology, 2022, 74, 1474-1476.	5.6	1
174	Defining remission in rheumatoid arthritis based on the Disease Activity Score 28. Nature Clinical Practice Rheumatology, 2006, 2, 124-125.	3.2	0
175	Socioeconomic and Disability Aspects. , 2013, , 653-658.		0
176	Methodological Quality of Studies of Endstage Renal Disease in Lupus Nephritis, 1970 to 2015. Journal of Rheumatology, 2017, 44, 626-630.	2.0	0
177	Repeated Spinal Mobility Measures and Their Association With Radiographic Damage in Ankylosing Spondylitis. ACR Open Rheumatology, 2021, 3, 413-421.	2.1	Ο
178	Risk of 30-day Readmission after Knee or Hip Replacement in Rheumatoid Arthritis and Osteoarthritis by non-Medicare and Medicare Payer Status. Journal of Rheumatology, 2021, , jrheum.201370.	2.0	0
179	Neurodynamics of expression coding in human fusiform. Journal of Vision, 2017, 17, 821.	0.3	0
180	Endogenous oscillatory activity modulates category tuning in ventral temporal cortex. Journal of Vision, 2018, 18, 553.	0.3	0